This small biotech could grow much larger with some good news from its pipeline.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to continue.

Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.

PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% ...

On April 13, UBS lifted its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $400 from $390. It reiterated a Buy rating on ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Cannara Biotech Inc (LOVFF) reports a 2% revenue increase and market share gains, despite a decline in net income and operating income.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...